Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.09 (-6.00%)
Close on Nov 12, 2026Market cap $35.81MP/E –Yield –
Serina Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Serina Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -18478.5%. For fiscal 2025 it was -18478.5%, against -30442.9% the year before. The highest annual figure on record is -99.2% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18478.5% | +11964.4 |
| FY2024 | Dec 31, 2024 | -30442.9% | −30343.6 |
| FY2023 | Dec 31, 2023 | -99.2% | +20415.5 |
| FY2022 | Dec 31, 2022 | -20514.7% | −15005.7 |
| FY2021 | Dec 31, 2021 | -5509.0% | −2711.2 |
| FY2020 | Dec 31, 2020 | -2797.8% | −2071.0 |
| FY2019 | Dec 31, 2019 | -726.8% | +78.7 |
| FY2018 | Dec 31, 2018 | -805.5% | −330.9 |
| FY2017 | Dec 31, 2017 | -474.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -6288.8% | +40131.2 |
| Q2 FY2025 | Jun 30, 2025 | -4280.8% | −4288.6 |
| Q3 FY2024 | Sep 30, 2024 | -37942.9% | −32898.0 |
| Q2 FY2024 | Jun 30, 2024 | -7580.4% | +5919.6 |
| Q1 FY2024 | Mar 31, 2024 | -46420.0% | −43213.3 |
| Q4 FY2023 | Dec 31, 2023 | 7.8% | +22282.8 |
| Q3 FY2023 | Sep 30, 2023 | -5044.8% | +12177.4 |
| Q2 FY2023 | Jun 30, 2023 | -13500.0% | −241.7 |
| Q1 FY2023 | Mar 31, 2023 | -3206.7% | +37833.3 |
| Q4 FY2022 | Dec 31, 2022 | -22275.0% | −15360.2 |
| Q3 FY2022 | Sep 30, 2022 | -17222.2% | −10247.2 |
| Q2 FY2022 | Jun 30, 2022 | -13258.3% | −7298.9 |
| Q1 FY2022 | Mar 31, 2022 | -41040.0% | −37134.6 |
| Q4 FY2021 | Dec 31, 2021 | -6914.8% | −5442.0 |
| Q3 FY2021 | Sep 30, 2021 | -6975.0% | −3501.1 |
| Q2 FY2021 | Jun 30, 2021 | -5959.5% | −697.2 |
| Q1 FY2021 | Mar 31, 2021 | -3905.4% | −525.6 |
| Q4 FY2020 | Dec 31, 2020 | -1472.8% | −978.1 |
| Q3 FY2020 | Sep 30, 2020 | -3473.9% | −2676.1 |
| Q2 FY2020 | Jun 30, 2020 | -5262.2% | −4356.4 |
| Q1 FY2020 | Mar 31, 2020 | -3379.8% | −2575.1 |
| Q4 FY2019 | Dec 31, 2019 | -494.7% | +578.1 |
| Q3 FY2019 | Sep 30, 2019 | -797.8% | −218.3 |
| Q2 FY2019 | Jun 30, 2019 | -905.8% | −445.9 |
| Q1 FY2019 | Mar 31, 2019 | -804.6% | +681.1 |
| Q4 FY2018 | Dec 31, 2018 | -1072.8% | – |
| Q3 FY2018 | Sep 30, 2018 | -579.5% | – |
| Q2 FY2018 | Jun 30, 2018 | -459.9% | – |
| Q1 FY2018 | Mar 31, 2018 | -1485.8% | – |
See a number that looks wrong?